Publications by authors named "Phyllis Chan"

Claim this Profile
U
Utilizing Minimal Physiologically Based Pharmacokinetic Modeling to Bridge Bevacizumab Pharmacokinetics from Adult to Pediatric Patients.
Olagoke Sule, Felix Stader, Nastya Kassir, Junyi Li, Phyllis Chan

AAPS J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effectiveness of a new parent education intervention program for primary school-age children and parents in Hong Kong.
Heidi Ka Ying Lo, Tommy Kwan Hin Fong, Calvin Pak Wing Cheng, Vivian Wai Yan Lui, Yiu Pan Wong, Phyllis Kwok Ling Chan

PLoS One· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer.
Phyllis Chan, Stephanie N Liu, Nathalie Gosselin, Zacharie Sauve, Mathilde Marchand, Pascal Chanu

CPT Pharmacometrics Syst Pharmacol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stronger together: a cross-SIG perspective on improving drug development.
Luke Fostvedt, Jiawei Zhou, Anna G Kondic, Ioannis P Androulakis, Tongli Zhang, Phyllis Chan

J Pharmacokinet Pharmacodyn· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors.
Colby S Shemesh, Yongsheng Wang, Andrew An, Hao Ding, Phyllis Chan

Cancer Chemother Pharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Consensus on Standard Outcome Measures for Neurodevelopmental Disorders: A Consensus Statement.
Melissa Mulraney, Umanga de Silva, Andria Joseph, Maria da Luz Sousa Fialho, Iain Dutia, Phyllis Chan

JAMA Netw Open· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.
Antonio Gonçalves, Mathilde Marchand, Phyllis Chan, Jin Y Jin, Jérémie Guedj

CPT Pharmacometrics Syst Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Pascal Chanu

Clin Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.
Colby S Shemesh, Phyllis Chan, Mathilde Marchand, Antonio Gonçalves, Shweta Vadhavkar

Clin Pharmacol Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data.
Nastya Kassir, Phyllis Chan, Steve Dang, René Bruno

Cancer Chemother Pharmacol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Pascal Chanu

Clin Cancer Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
Stephanie N Liu, Mathilde Marchand, Xiaoyan Liu, Gladys Ingle, Vidya Maiya, Phyllis Chan

J Clin Pharmacol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-Terminal Lysine Processing of IgG in Human Suction Blister Fluid: Implications for Subcutaneous Administration.
Luladey Ayalew, Phyllis Chan, Zhilan Hu, Amy Shen, Eileen Duenas

Mol Pharm· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.
Weize Huang, Felix Stader, Phyllis Chan, Colby S Shemesh, Yuan Chen, Pascal Chanu

Front Pharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applications of Model-Based Meta-Analysis in Drug Development.
Phyllis Chan, Kirill Peskov, Xuyang Song

Pharm Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of mindfulness parent training on parenting stress and children's ADHD-related behaviors: A systematic review and meta-analysis.
Clara S C Lee, Ka-Hin Ng, Phyllis C K Chan, Xianwei Peng

Hong Kong J Occup Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study.
Kenta Yoshida, Phyllis Chan, Mathilde Marchand, Rong Zhang, Benjamin Wu

AAPS J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update to improve reproducibility and interpretability: A response to "Machine Learning for Tumor Growth Inhibition".
Phyllis Chan, James Lu, René Bruno, Jin Y Jin

CPT Pharmacometrics Syst Pharmacol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
Benjamin Wu, Nitzan Sternheim, Priya Agarwal, Julia Suchomel, Shweta Vadhavkar, Phyllis Chan

Clin Transl Sci· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Enriqueta Felip, Mauricio Burotto, Zanete Zvirbule, Luis A Herraez-Baranda, Pascal Chanu, Phyllis Chan, Mathilde Marchand

Clin Pharmacol Drug Dev· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework.
Phyllis Chan, Mathilde Marchand, Kenta Yoshida, Shweta Vadhavkar, Nina Wang

CPT Pharmacometrics Syst Pharmacol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
Phyllis Chan, Han Ting Ding, Bianca M Liederer, Jialin Mao, Paula Belloni

Clin Transl Sci· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.
Colby S Shemesh, Phyllis Chan, Hui Shao, Derek-Zhen Xu, Daniel Combs

Liver Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-dependent population PK models of single-agent atezolizumab in patients with cancer.
Mathilde Marchand, Rong Zhang, Phyllis Chan, Valerie Quarmby, Marcus Ballinger

Cancer Chemother Pharmacol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled trial on the comparative effectiveness of mindfulness-based cognitive therapy and health qigong-based cognitive therapy among Chinese people with depression and anxiety disorders.
Sunny H W Chan, Wendy W K Chan, June Y W Chao, Phyllis K L Chan

BMC Psychiatry· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis